Mainz Biomed B.V. (MYNZ)
Automate Your Wheel Strategy on MYNZ
With Tiblio's Option Bot, you can configure your own wheel strategy including MYNZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MYNZ
- Rev/Share 0.2099
- Book/Share 0.8022
- PB 1.4461
- Debt/Equity 1.2265
- CurrentRatio 0.5154
- ROIC -2.9231
- MktCap 4746980.0
- FreeCF/Share -4.9602
- PFCF -0.3044
- PE -0.1923
- Debt/Assets 0.3156
- DivYield 0
- ROE -4.4279
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MYNZ | Maxim Group | -- | Buy | -- | $14 | Feb. 14, 2025 |
News
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
Published: January 14, 2026 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
2 Small-Cap Biotechs That Could Reward Patient Investors
Published: December 12, 2025 by: MarketBeat
Sentiment: Negative
Speculative investors and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement.
Read More
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Expands into Switzerland with labor team w
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
About Mainz Biomed B.V. (MYNZ)
- IPO Date 2021-11-05
- Website https://mainzbiomed.com
- Industry Medical - Diagnostics & Research
- CEO Guido Baechler
- Employees 19